Systematic analysis of SCN5A variants associated with inherited cardiac diseases.
Hermida. Alexis A; Jedraszak. Guillaume G; Ader. Flavie F; Denjoy. Isabelle I; Fressart. Véronique V; Maury. Phillipe P; Beyls. Christophe C; Bloch. Adrien A; Clerici. Gaël G; Daire. Elise E; Defaye. Pascal P; Dupin-Deguine. Delphine D; Garçon. Loic L; Klug. Didier D; Ginglinger. Emmanuelle E; Hermida. Jean-Sylvain JS; Jesel. Laurence L; Khraiche. Diala D; Kubala. Maciej M; Lacotte. Jérôme J; Laredo. Mikael M; Leenhardt. Antoine A; Le Guillou. Xavier X; Lesaffre. Francois F; Maltret. Alice A; Magnin-Poull. Isabelle I; Marijon. Eloi E; Nambot. Sophie S; Neyroud. Nathalie N; Ninni. Sandro S; Palmyre. Aurélien A; Pasquie. Jean Luc JL; Proukhnitzky. Julie J; Reant. Patricia P; Richard. Pascale P; Rollin. Anne A; Rooryck. Caroline C; Sacher. Frédéric F; Schaefer. Elise E; Vernier. Agathe A; Winum. Pierre-François PF; Wahbi. Karim K; Waintraub. Xavier X; Waldmann. Victor V; Weber. Sacha S; Zouaghi. Amir A; Charron. Philippe P; Extramiana. Fabrice F; Gandjbakhch. Estelle E
Key Findings
- About 70% of pathogenic SCN5A variants are linked to a single, well‑known electrical heart disorder, mainly Brugada syndrome.
- Roughly 20% of the variants show overlap syndromes or pleiotropy, meaning they can affect multiple heart functions.
- SCN5A variants are almost never the direct cause of dilated cardiomyopathy (only 8 out of 9,960 cardiomyopathy cases).
Practical Outcomes
- For DIY health enthusiasts, this study suggests that genetic testing for SCN5A is useful mainly for identifying risk of arrhythmias, not for guiding any specific supplement or peptide regimen. There are no actionable protocols or dosage recommendations derived from these findings.
Summary
Most harmful changes in the SCN5A gene lead to heart rhythm problems like Brugada syndrome, while only a small share cause mixed or unclear heart issues, and it is very rare for these changes to cause dilated cardiomyopathy.
Abstract
SCN5A variants are associated with a spectrum of cardiac electrical disorders with clear phenotypes. However, they may also be associated with complex phenotypic traits like overlap syndromes or pleiotropy, which have not been systematically described. In addition, the involvement of SCN5A in dilated cardiomyopathies (DCMs) remains controversial. We aimed to evaluate the different phenotypes associated with pathogenic (P)/likely pathogenic (LP) SCN5A variants and to determine the prevalence of pleiotropy in a large multicentric cohort of P/LP SCN5A variant carriers. The DNA of 13,510 consecutive probands (9960 with cardiomyopathies) was sequenced with a custom panel of genes. Individuals carrying a heterozygous single P/LP SCN5A variant were selected and phenotyped. The study included 170 P/LP variants found in 495 patients. Of them, 119 (70%) were exclusively associated with a single well-established phenotype: 91 with Brugada syndrome, 15 with type 3 long QT syndrome, 6 with progressive cardiac conduction disease, 4 with multifocal ectopic Purkinje-related premature contractions, and 3 with sick sinus syndrome. Thirty-two variants (19%) were associated with overlap syndromes or pleiotropy. The 19 remaining variants (11%) were associated with atypical or unclear phenotypes. Of those, 8 were carried by 8 patients presenting with DCM with a debatable causative genotype/phenotype link. Most P/LP SCN5A variants were found in patients with primary electrical disorders, mainly Brugada syndrome. Nearly 20% were associated with overlap syndromes or pleiotropy, underscoring the need for comprehensive phenotypic evaluation. The concept of SCN5A variants causing DCM is extremely rare (8/9960) if not questionable.
Study Information
pubmed
2024
2024-08-10T00:00:00.000Z
10.1016/j.hrthm.2024.08.018
9
32